GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Haemonetics Corp (NYSE:HAE) » Definitions » Median PS Value

Haemonetics (Haemonetics) Median PS Value

: $87.23 (As of Today)
View and export this data going back to 1991. Start your Free Trial

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Haemonetics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $24.734. Haemonetics's 10-Year median PS Ratio is 3.5267. Therefore, the Median PS Value for today is $87.23.

As of today (2024-04-18), Haemonetics's share price is $84.88. Haemonetics's Median PS Value is $87.23. Therefore, Haemonetics's Price to Median PS Value for today is 0.97.

The historical rank and industry rank for Haemonetics's Median PS Value or its related term are showing as below:

HAE' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.68   Med: 1.16   Max: 2.81
Current: 0.97

During the past 13 years, the highest Price to Median PS Value of Haemonetics was 2.81. The lowest was 0.68. And the median was 1.16.

HAE's Price-to-Median-PS-Value is ranked worse than
61.94% of 310 companies
in the Medical Devices & Instruments industry
Industry Median: 0.77 vs HAE: 0.97

Haemonetics Median PS Value Historical Data

The historical data trend for Haemonetics's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haemonetics Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Median PS Value
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.20 46.26 42.23 51.59 73.11

Haemonetics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Median PS Value Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 64.70 73.11 80.55 84.16 87.23

Competitive Comparison

For the Medical Instruments & Supplies subindustry, Haemonetics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Haemonetics Price-to-Median-PS-Value Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Haemonetics's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Haemonetics's Price-to-Median-PS-Value falls into.



Haemonetics Median PS Value Calculation

Haemonetics's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=24.734*3.5267
=87.23

10-Year Median PS Ratio is 3.5267.
Haemonetics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $24.734.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Haemonetics  (NYSE:HAE) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Haemonetics's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=84.88/87.23
=0.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Haemonetics Median PS Value Related Terms

Thank you for viewing the detailed overview of Haemonetics's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Haemonetics (Haemonetics) Business Description

Traded in Other Exchanges
Address
125 Summer Street, Boston, MA, USA, 02110
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Executives
Stewart W Strong officer: President, Global Hospital C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Anila Lingamneni officer: EVP, Chief Technology Officer HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Charles J Dockendorff director COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Diane M Bryant director 2200 MISSION COLLEGE BLVD, SANTA CLARA CA 95054
Josep Llorens officer: EVP, Global Manufacturing HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Michelle L Basil officer: EVP and General Counsel HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Farris Maryanne Maunsell officer: VP, Chief Accounting Officer C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Roy Galvin officer: President, Global Plasma & BC C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Laurie A. Miller officer: SVP, Human Resources C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Mark W Kroll director PO BOX 23, CRYSTAL BAY MN 55323
Dan Goldstein officer: VP, Corporate Controller HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Christopher Simon, director, officer: President & CEO HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
James Darecca officer: EVP, Chief Financial Officer C/O HAEMONETICS CORPORATION, 125 SUMMER STREET, BOSTON MA 02110
Burke William P. Mr. officer: EVP, Chief Financial Officer HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Lloyd Emerson Johnson director 16737 NEW PROVIDENCE LANE, CHARLOTTE NC 28277